Irras
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
IRRAS was a Stockholm-based medical technology company focused on neurocritical care, selling the IRRAflow system and the Hummingbird intracranial-pressure (ICP) monitoring product line to hospitals worldwide through direct sales in the US and Europe plus distribution partners. Listed on Nasdaq Stockholm in November 2017 (raising SEK 293 million), the company acquired the Hummingbird ICP assets in 2019 and grew revenue for eight consecutive quarters through 2022. Facing an immediate funding need and high insolvency risk, it became the target of a distressed public cash offer by a shareholder consortium; IR Holding Bidco took control in September 2023 and the shares were delisted from Nasdaq Stockholm on November 3, 2023.
02 / Irras FAILURE REASONS
Failure reasons
IRRAS burned cash faster than revenue grew: it reported a loss after tax of SEK -70.3 million in just the first half of 2022, and the board estimated it needed at least SEK 250 million more to reach positive cash flow. An extensive financing evaluation in 2023 found no concrete alternatives. Dependent on a SEK 60 million short-term loan from shareholder Bacara Holdings (falling due September 15, 2023, with the company's patents pledged as collateral), IRRAS faced an imminent risk of default and insolvency, leading the independent bid committee to recommend shareholders accept the consortium's SEK 0.18-per-share rescue offer.
03 / EVENT HISTORY
Events in the structured record
- IPO
IRRAS lists on Nasdaq Stockholm First North Premier, raising SEK 293 million from about 600 new shareholders to fund its growth strategy.
- Hummingbird acquisition
IRRAS acquires the Hummingbird ICP monitoring assets (cranial access bolts, parenchymal ICP monitoring) and launches the product line in the US in December.
- Distressed public offer
A consortium (Legacy Capital, Spetses, Bacara, Lexington, Kleanthis Xanthopoulos and others) via IR Holding Bidco announces a public cash offer of SEK 0.18 per share; the independent bid committee recommends acceptance as the company faces imminent insolvency on a SEK 60 million short-term loan.
- Take-private and delisting
IR Holding completes the offer, controlling 87.9% of shares (the SEK 60 million loan is converted to equity at SEK 0.18 per share); Nasdaq Stockholm delists IRRAS shares on November 3, 2023.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
IRRAS raised SEK 293 million in its November 2017 Nasdaq Stockholm listing.
- 02
On June 30, 2023 the IR Holding Bidco consortium offered SEK 0.18 in cash per share; by completion it controlled 87.9% of IRRAS shares, with the SEK 60 million short-term loan plus accrued interest converted into 338,264,840 new shares by set-off.
- 03
The last day of trading was November 3, 2023; the company went private under the consortium. Its patents had been pledged to Bacara Holdings as collateral under the short-term loan facility.